ClinicalTrials.gg
CompletedNCT00823875Updated Dec 1, 2010

Study of Cilostazol and Probucol Alone and in Combination on Atherosclerosis Related Biomarker---atherosclerosis Cerebral Infarction Patient as Study Subject

A Phase 4 interventional study of Cilostazol group and Probucol group in Atherosclerosis Cerebral Infarction, sponsored by Otsuka Beijing Research Institute. Completed at 1 site in China. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2010-12-01.

Sponsored by Otsuka Beijing Research Institute (part of Otsuka Holdings Co., Ltd.) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing cilostazol in Cerebral Infarction — 1 open to participants now, 1 under way, none of them phase 3. Cilostazol · Cerebral Infarction.

Planned enrollment
10th of 10
200 · median 594
Started
2009
the only one that year
Phase 4
8 of 10
1 open now
Registered
8th of 10
by date
Lead sponsor
2 of 10
Otsuka Beijing Research Institute

Among the 10 studies testing cilostazol in Cerebral Infarction, this one is the 10th largest by planned enrollment, is the only one that started in 2009, is one of 8 in phase 4, and was the 8th registered.

Cerebral Infarction

219 studies on the registry are indexed under Cerebral Infarction; 46 are open to participants now.

Browse Cerebral Infarction studies →

Open to participants now

1 of the 10 studies testing cilostazol in Cerebral Infarction is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About cilostazol

Cilostazol: first FDA approval 1999 (PLETAL). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 27 Cerebral Infarction studies recruiting now, 19 (70%) set no upper age limit and none (0%) stop at 75 or younger; 2 take children under 18; 2 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing cilostazol in Cerebral Infarction, or all of them as a file.
02

Study summary

Randomized, control, open label, multicentre clinical study. The patient who are in accordance with subject inclusion and exclusion criteria will be randomized to A group: Routine treatment B group: Routine treatment+ Cilostazol; C group : Routine treatment + Probucol; D group: Routine treatment+ Cilostazol+ Probucol .

Read the detailed description

Efficacy index:

After 12 weeks of treatment, the change difference of arteriosclerosis related biomarker between 4 modality groups.

Pharmacokinetics:

After 12 weeks of treatment, the study medication plasma concentration including of Probucol ,Cilostazol , Cilostazol metabolism OPC-13015 and OPC-13213 will be measured.

Safety evaluation:

Analysis the abnormality of Adverse Event, Vital Sign, Physical Examination, 12-lead ECG, and Laboratory Tests (including blood routine examination, routine urine analysis, blood biochemistry examination, glycosylated hemoglobin) in 4 modality groups.

03

Conditions studied

  • Atherosclerosis Cerebral Infarction
04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 40~80-year-old male or female
  2. By brain CT or MRI result, cerebral infarction is clarified diagnosis within 1 year
  3. With atherosclerosis, atherosclerosis should meet at least one of the conditions as below:

    • Clarified diagnosis of type 2 diabetes before
    • Clarified diagnosis of primary hypertension before
    • Clarified diagnosis of Atherosclerotic stenosis in any 2 or more than 2 regions as cerebral artery, carotid, extremity artery and coronary by conformation of ultrasonic or angiography result
  4. Has Aspirin regularly for more than 1 month before registration
  5. Form signature

Exclusion criteria

Exclusion criteria:

  1. Has an allergic history to study drugs( including of Probucol and Cilostazol) and Aspirin
  2. Had lipid-lowing agents within the last 3 months ( except Statins)
  3. Had antiplatelet or anticoagulation agents within the last 3 months (except Aspirin)
  4. Had acute cerebral infarction within the last 1 month
  5. Has cardiogenic cerebral embolism
  6. At the registration ,Modified Rankin Scale ≥ 4
  7. Hemorrhagic tendency or hemorrhagic disease (such as cerebral hemorrhage, gastrointestinal tract hemorrhage, etc.)
  8. Had a myocardial infarction, angina pectoris within the last 3 months
  9. Congestive heart failure
  10. Is pregnant, is potentially pregnant, or is breastfeeding
  11. Severe hepatic inadequacy or severe renal inadequacy ( or ALT is 2.5 times higher than the value range, or serum creatinine is 1.2 times higher than the upper limit of the normal value range)
  12. Persistent or hardly controlled hypertension (such as malignant hypertension, BP> 160/100 mmHg)
  13. Severe ventricular arrhythmia (such as multiple and multifocal premature ventricular contractions)
  14. Has a medical history that includes a cardiac syncope or a primary syncope
  15. Has a condition that may prolong (such as congenital long QT syndrome, taking drugs which prolong QT interval, hypokalemia or hypomagnesemia, etc.)
  16. Has severe diseases (such as, malignant tumor, severe anaemia, severe hematologic diabetes mellitus ketoacidosis, nonketotic hyperosmolar diabetic coma, etc.)
  17. Registered other clinical trails within the last 3 months
  18. Has vasculitis, moyamoya disease and other non-atherosclerosis vascular diseases
  19. Other conditions that could exclude the subject from this study by doctor's judgment
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    1

    Drug: Cilostazol group

  • Experimental
    2

    Drug: Probucol group

  • Experimental
    3

    Drug: Cilostazol + Probucol group

  • Other
    4

    Control Group

    Drug: control group

Interventions

  • Cilostazol: At first, 50 mg (1 tablets) Bid, PO after breakfast and dinner. After administration of study drug for 1 week, and if patient has no significant discomfort, the drug dosage will increase to 100mg(2 tablets)Bid.

    Also known as: Pletaal

  • Probucol: 250 mg (1 tablet) Bid, PO after breakfast and dinner

    Also known as: Changtai

  • DrugCilostazol + Probucol group

    Drug pages: Cilostazol · Probucol

    Cilostazol: At first, 50 mg (1 tablets) Bid, PO after breakfast and dinner. After administration of study drug for 1 week, and if patient has no significant discomfort, the drug dosage will increase to 100mg(2 tablets)Bid. Probucol: 250 mg (1 tablet) Bid, PO after breakfast and dinner

    Also known as: Pletaal and Changtai

  • Drugcontrol group

    routine treatment

    Also known as: Routine Treatment

06

What researchers measure

Primary outcomes

  1. After 12 weeks of treatment, the change difference of arteriosclerosis related biomarker between 4 modality groups.

    Time frame: 12 week

07

Study locations

1 site
  • First Affliate Hospital of Beijing University
    Beijing, China
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2009, a primary completion of Dec 2009 and a completion of Jul 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 15, 2009
First posted
Jan 16, 2009
Start
Mar 2009
Primary completionActual
Dec 2009
CompletionActual
Jul 2010
Last update
Dec 1, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 1, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00823875
First posted
Jan 16, 2009
Start date
Mar 2009
Primary completion
Dec 2009
Completion
Jul 2010
Last update
Dec 1, 2010

Study contacts

Yining Huang, M.D.
principal investigator · Peking University First Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cilostazol · Probucol

Start the discussion